Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05791474
Title ATI-2231 With in Advanced Solid Tumor Malignancies Followed by ATI-2231 in Combination With Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications
Therapies
Age Groups: adult | senior
Covered Countries


No variant requirements are available.